#ExpertAnswers: Nataliia Beztsinna and Marten Hornsveld on Pre-Clinical Immuno-OncologyDarius Soo Lum
Nataliia Beztsinna and Marten Hornsveld describe how the tumor microenvironment modulates clinical responses and how patient-derived ex vivo and engineered in vitro models can be used for pre-clinical immuno-oncology testing.
Cancer Immunotherapy: Viruses, Vaccines, and other Immuno-Oncology Treatments
In this blog post, current cancer immunotherapy treatments are discussed, as well as some future directions for this rapidly developing field.
Industry Insights with Crown Bioscience: Analyzing the Suppressive TME in In Vitro Based AssaysDarius Soo Lum
Nataliia Beztsinna and Marten Hornsveld from Crown Bioscience talk about native and reconstituted TME assays, how they can help in the preparation for clinical trials, and what kinds of therapies in development would benefit the most from this kind of testing.
Industry Insights with Crown Bioscience: Targeting T Cells Within the Cancer-Immunity Cycle
In this episode of Industry Insights, Saskia De Man, PhD, Marrit Putker, PhD, and Pirouz Daftarian, PhD, from Crown Bioscience discuss assays and methods for evaluating T cell therapeutics, including organoids, co-cultures, and high content imaging.
Industry Insights with Crown Bioscience: In Vitro Technologies for Studying the Cancer-Immunity Cycle
In this episode of Industry Insights, Rajendra Kumari, PhD, and Gera Goverse, PhD, from Crown Bioscience answer questions about in vivo, in vitro, and ex vivo technologies and methods that can be used for immuno-oncology research along each step of the cancer-immunity cycle.
The Cancer-Immunity Cycle: Methods, Challenges, and Opportunitiesliamisc
In this series, experts provide an overview of technologies, techniques, challenges, and emerging research questions along each step of the cancer immunity cycle.
Analyzing the Suppressive TME in in Vitro Based Assays
Experts describe suppressive tumor immune microenvironment compartments and patient-derived tissue technologies capable of recapitulating the TME for clinically-relevant studies.
The Cancer-Immunity Cycle: Research Solutions for Preclinical Immuno-Oncology
Cancer immunotherapy has undoubtedly expanded the cancer treatment landscape and improved patient outlook, which can in part be attributed to the recognition of the importance of the cancer-immunity cycle as a whole. In this blog, we provide an overview of the cancer-immunity cycle and highlight some preclinical models that can facilitate cancer immunotherapy research.
#ExpertAnswers: Bin Xie on Drug Development for Immuno-OncologyDarius Soo Lum
Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.
Current and Novel Immuno-Oncology Drug Evaluation Methods via Humanized Mouse Models
Dr. Bin Xie discusses the current immuno-oncology drug development landscape, different humanized mouse models available for drug testing, and the investigation of potential mechanisms via imaging mass cytometry.